researchers estimated weight loss would be 20.7% for the 7.2 milligram group, 17.5% for the 2.4 milligram group and 2.4% for the placebo group. Novo Nordisk announced the study results on Jan.

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average ... doses of Zepbound and Wegovy against one another. Results from the SURMOUNT ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe ... vice-president Martin Holst Lange said: “Results from STEP UP further strengthen the ...

Results of early-stage trial of injectable ... obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

A major analysis of more than 1.2 million medical records has found popular diabetes and weight loss drugs, including Ozempic and Wegovy ... This results in the lowering of the blood's glucose ...